The effect of montelukast on bronchial hyperreactivity in preschool children

Chest

Volumn 131, Issue 1, 2007, Pages 180-186

  Hakim, Fahed ^a   Vilozni, Daphna ^a   Adler, Adi ^a   Livnat, Galit ^a   Tal, Asher ^b   Bentur, Lea ^a,c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c MEYER CHILDREN S HOSPITAL   (Israel)

Author keywords

Bronchial reactivity; Leukotrienes; Pediatric asthma; Preschool

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; METHACHOLINE; MONTELUKAST; PLACEBO;

ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CHEWABLE TABLET; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 33846304206     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-1402     Document Type: Article

References (39)

1. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:e48
2. Michele TM, Knorr B, Vadas EB, et al. Safety of chewable tablets for children. J Asthma 2002; 39:391-403
3. van Adelsberg J, Moy J, Wei LX, et al. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin 2005; 21:971-979
4. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial; Pediatric Montelukast Study Group. JAMA 1998 15; 279:1181-1186
5. Bentur L, Beck R, Shinawi M, et al. Wheeze monitoring in children for assessment of nocturnal asthma and response to therapy. Eur Respir J 2003; 21621-21626
6. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171:315-322
7. Lee MY, Lai YS, Yang KD, et al. Effects of montelukast on symptoms and eNO in children with mild to moderate asthma. Pediatr Int 2005; 47:622-626
8. Bisgaard H, Nielsen KG. Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children. Am J Respir Crit Care Med 2000; 162:187-190
9. Cockcroft DW, Killian DN, Mellon JJ, et al. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7:235-243
10. Anderson SD. Challenge tests to assess airway hyperresponsiveness and efficacy of drugs used in the treatment of asthma. J Aerosol Med 1996; 9:95-109
11. Sterk PJ, Fabbri LM, Quanjer PH, et al. Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993; 6(suppl):53-83
12. National Heart, Lung, and Blood Institute. International consensus report on diagnosis and treatment of asthma: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda, Maryland 20892-Publication No. 92-3091, March 1992. Eur Respir J 1992; 5:601-641
13. Cockcroft DW. Bronchoprovocation methods: direct challenges. Clin Rev Allergy Immunol 2003; 24:19-26
14. Eigen H, Bieler H, Grant D, et al. Spirometric pulmonary function in healthy preschool children. Am J Respir Crit Care Med 2001; 163:619-623
15. Nystad W, Samuelsen SO, Nafstad P, et al. Feasibility of measuring lung function in preschool children. Thorax 2002; 57:1021-1027
16. Zapletal A, Chalupova J. Forced expiratory parameters in healthy preschool children (3-6 years of age). Pediatr Pulmonol 2003; 35:200-207
17. Vilozni D, Barker M, Jellouschek H, et al. An interactive computer-animated system (SpiroGame) facilitates spirometry in pre-school children. Am J Respir Crit Care Med 2001; 164:2200-2205
18. Vilozni D, Barak A, Efrati O, et al. The role of computer games in measuring spirometry in healthy and "asthmatic" preschool children. Chest 2005; 128:1146-1155
19. Bentur L, Beck R, Elias N, et al. Methacholine bronchial provocation measured by spirometry versus wheeze detection in preschool children. BMC Pediatr 2005 28; 5:19
20. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics; 2002. J Allergy Clin Immunol 2002; 110:8141-5219
21. Aurora P, Stocks J, Oliver C, et al. Quality control for spirometry in preschool children with and without lung disease. Am J Respir Crit Care Med 2004; 169:1152-1159
22. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
23. American Thoracic Society. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med 2000; 161:309-329
24. Springer C, Godfrey S, Pickard E, et al. Efficacy and safety of niethacholine bronchial challenge performed by auscultation in young asthmatic children. Am J Respir Crit Care Med 2000; 162:857-860
25. Hauschke D, Steinijans VW, Diletti E. A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Tber Toxicol 1990; 28:72-78
26. Center for Drug Evaluation and research (CDER). Guidance for industry: statistical approaches to establishing bioequivalence. Available at: http://www.fda.gov/cder/guidance/index. htm. Accessed January 31, 2001
27. SAS Institute. SAS for personal computers: release 9.1.3. Cary, NC: SAS Institute
28. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 59:1043-1051
29. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999; 353:57-62
30. Riccioni G, D'Orazio N, Di Ilio C, et al. Effectiveness and safety of montelukast versus budesonide at various doses on bronchial reactivity in subjects with mild persistent asthma. Clin Ter 2002; 153:317-321
31. de Benedictis FM, del Giudice MM, Forenza N, et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J 2006; 28:291-295
32. Wilson AM, Dempsey OJ, Sims EJ, et al. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119: 1021-1026
33. Bisgaard H, Loland L, Oj JA. NO in Exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160:1227-1231
34. van Rensen EL, Straathof KC, Veselic-Charvat MA, et al. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999; 54:403-408
35. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006 15; 173:379-385
36. Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci 1995; 16:304-330
37. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001; 56:7-11
38. Straub DA, Minocchieri S, Moeller A, et al. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 2005; 127:509-514
39. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242